Dear Editor,

Lichen planopilaris (LPP), a follicular form of lichen planus, is a rare inflammatory lymphocyte-mediated disorder that selectively involves hair follicles. LPP leads to follicular destruction and, consequently, cicatricial alopecia [1]. It frequently occurs on the vertex, but any region of the scalp can be involved [2]. Although noninflammatory body hair loss has been described, mainly in association with LPP variants such as frontal fibrosing alopecia (FFA) and Lassueur-Graham-Little-Piccardi Syndrome (LGLPS), inflammatory alopecic patches as seen on the scalp seem to be an uncommon finding on other parts of the body [3]. We report a case of a 38-year-old male presenting with scarring body hair loss as the sole manifestation of LPP.

A 38-year-old male patient presented to our hair clinic with a 2-year history of progressive body hair loss. It had started with an isolated patch of alopecia on his right lower limb. Gradually, he developed new areas of alopecia on his left limb and, after 1 year, he also noticed lesions on the upper limbs. The patient reported that intense itching preceded hair loss. Previous treatments included multiple topical antifungal agents, which were all ineffective. Physical examination revealed well-demarcated extensive areas of alopecia on the limbs (fig. 1) with preserved sensory perception. Dermoscopy of the hair-bearing margins showed perifollicular erythema, discrete perifollicular scaling and some broken hairs (fig. 2). On scalp examination, there were only signs of early androgenetic alopecia on the vertex region, without clinical or dermoscopic signs of inflammation. The eyebrows, axillary and pubic regions were unaffected. Additional laboratory examinations including treponemal tests, thyroid function and antinuclear antibodies were all normal. Dermoscopy-guided punch biopsy of an area showing perifollicular erythema and scaling on the right arm revealed perifollicular lichenoid inflammation and scarring, confirming the clinical diagnosis of LPP (fig. 3). At first, treatment with doxycycline 100 mg/day and topical clobetasol 3 times a week on the hair-bearing margins were prescribed. After 3 months, the patient reported resolution of symptoms (pruritus). As expected, hair regrowth was not observed. Due to the great extent of body hair loss and its scarring nature, the need of therapy was discussed with the patient, who opted for no treatment. However, follow-up consultations are scheduled every 3 months, in order to monitor symptoms and scalp hair.

Fig. 1

Clinical images showing alopecic patches on the thighs (a), legs (b) and arms (c). a Pronounced perifollicular erythema can be seen. c There is a marked contrast between alopecic and normal hairy areas.

Fig. 1

Clinical images showing alopecic patches on the thighs (a), legs (b) and arms (c). a Pronounced perifollicular erythema can be seen. c There is a marked contrast between alopecic and normal hairy areas.

Close modal
Fig. 2

Dermoscopy of the hair-bearing margins shows perifollicular erythema, discrete perifollicular scaling and some broken hairs. ×20. Picture taken with Fotofinder Handyscope® Teachscreen Software, Bad Birnbach, Germany.

Fig. 2

Dermoscopy of the hair-bearing margins shows perifollicular erythema, discrete perifollicular scaling and some broken hairs. ×20. Picture taken with Fotofinder Handyscope® Teachscreen Software, Bad Birnbach, Germany.

Close modal
Fig. 3

Horizontal section of a punch biopsy specimen at the level of the upper follicles showing perifollicular lichenoid inflammatory infiltrate and concentric fibrosis. Hematoxylin and eosin. ×10.

Fig. 3

Horizontal section of a punch biopsy specimen at the level of the upper follicles showing perifollicular lichenoid inflammatory infiltrate and concentric fibrosis. Hematoxylin and eosin. ×10.

Close modal

Although classic LPP can occur on any part of the scalp, it usually affects the vertex region, typically presenting as patches of scarring alopecia with inflammatory signs on the hair-bearing margins, such as perifollicular erythema and scaling. Pain, itching or burning sensations may be associated and indicate disease activity [2,4]. The possibility of body hair involvement is well established in some variants of LPP, such as FFA and LGLPS. FFA is mainly characterized by progressive recession of the frontotemporal hairline with eyebrow involvement; noninflammatory body hair loss is reported in up to 24% of FFA patients [5,6]. In LGLPS, patches of scarring hair loss on the scalp and disseminated follicular hyperkeratosis are classically described in association with noncicatricial alopecia of the axillary and pubic regions [1,7]. However, in classic LPP, body hair involvement has been poorly described. Even though it is mentioned in the literature [1], a clear description of its nature (scarring vs. nonscarring), clinical presentation (inflammatory vs. noninflammatory) and incidence seem to be lacking. Furthermore, in our literature review, we were unable to find cases similar to that described herein, in which inflammatory patches of scarring alopecia on the limbs were the sole manifestation of LPP.

Differentials that should be considered in patients presenting with body hair loss include, among many others, alopecia areata, hypothyroidism, mycosis fungoides, syphilis and leprosy [8]. However, epidemiological history, clinical presentation and dermoscopic findings pointed to the diagnosis of LPP, which was confirmed through histopathology [9,10].

In conclusion, we present an unusual case of LPP presenting with isolated patchy alopecia on the limbs. The delay to diagnosis in this case highlights the need for strong clinical suspicion and reinforces our recommendation to consider LPP as a differential diagnosis in patients with body hair loss.

Statement of Ethics

The patient's consent has been obtained.

Disclosure Statement

The authors declare no conflicts of interest. There were no funding sources.

1.
Assouly P, Reygagne P: Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg 2009;28:3-10.
2.
Ramos-e-Silva M, Pirmez R: Red face revisited: disorders of hair growth and pilosebaceous unit. Clin Dermatol 2014;32:784-799.
3.
Cevasco NC, Bergfeld WF, Remzi BK, de Knott HR: A case-series of 29 patients with lichen planopilaris: the Cleveland Clinic Foundation experience on evaluation, diagnosis, and treatment. J Am Acad Dermatol 2007;57:47-53.
4.
Soares VC, Mulinari-Brenner F, Souza TE: Lichen planopilaris epidemiology: a retrospective study of 80 cases. An Bras Dermatol 2015;90:666-670.
5.
Pirmez R, Donati A, Valente NS, Sodre CT, Tosti A: Glabellar red dots in frontal fibrosing alopecia: a further clinical sign of vellus follicle involvement. Br J Dermatol 2014;170:745-746.
6.
Vaño-Galván S, Molina-Ruiz A, Serrano-Falcón, Arias-Santiago, Rodrigues-Barata AR, Garnacho-Saucedo G, et al: Frontal fibrosing alopecia: a multicentre review of 355 patients. J Am Acad Dermatol 2014;70:670-678.
7.
Kakizaki P, Donati A, Valent N, Yuriko S, Romiti R: Síndrome de Graham-Little-Piccardi-Lassueur: variante disseminada de líquen plano follicular. Dermatol Online J 2015;21:13030/qt8c98j2d7.
8.
Bi MY, Curry JL, Christiniano AM, Hordinsky MK, Norris DA, Price VH, et al: The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 2011;64:53-63.
9.
Friedman P, Sabban EC, Marucci C, Peralta R, Cabo H: Dermoscopic findings in different clinical variants of lichen planus. Is dermoscopy useful? Dermatol Pract Concept 2015;5:51-55.
10.
Duque-Estrada B, Tamler C, Sodré CT, Barcaui CB, Pereira FB: Dermoscopy patterns of cicatricial alopecia resulting from discoid lupus erythematosus and lichen planopilaris. An Bras Dermatol 2010;85:179-183.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.